A Novel Insulin Sensitizer (S15511) Enhances Insulin-stimulated Glucose Uptake in Rat Skeletal Muscles

Abstract

Type 2 diabetes is preceded by the presence of skeletal muscle insulin resistance, and drugs that increase insulin sensitivity in skeletal muscle prevent the disease. S15511 is an original compound with demonstrated effects on insulin sensitivity in animal models of insulin resistance. However, the mechanisms behind the insulin-sensitizing effect of S15511 are unknown. The aim of our study was to explore whether S15511 improves insulin sensitivity in skeletal muscles. Insulin sensitivity was assessed in skeletal muscles from S15511-treated rats by measuring intracellular insulin-signaling activity and insulin-stimulated glucose transport in isolated muscles. In addition, GLUT4 expression and glycogen levels were assessed after treatment. S15511 treatment was associated with an increase in insulin-stimulated glucose transport in type IIb fibers, while type I fibers were unaffected. The enhanced glucose transport was mirrored by a fiber type-specific increase in GLUT4 expression, while no improvement in insulin-signaling activity was observed. S15511 is a novel insulin sensitizer that is capable of improving glucose homeostasis in nondiabetic rats. The compound enhances skeletal muscle insulin sensitivity and specifically targets type IIb muscle fibers by increasing GLUT4 expression. Together these data show S15511 to be a potentially promising new drug in the treatment and prevention of type 2 diabetes.

Key words

insulin sensitivity - type 2 diabetes - skeletal muscle - insulin sensitizer - GLUT4 - Wistar rat - insulin signaling

References

• 1 Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women.  N Engl J Med. 2001;  345 790-797
• 2 Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS. Diabetes trends in the U.S.: 1990-1998.  Diabetes Care. 2000;  23 1278-1283
• 3 UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).  Lancet. 1998;  352 854-865
• 4 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853
• 5 Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
• 6 Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.  Diabetes. 2005;  54 1150-1156
• 7 Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.  Lancet. 2002;  359 2072-2077
• 8 Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.  Lancet. 2006;  368 1096-1105
• 9 Knowler WC, Narayan KM, Hanson RL, Nelson RG, Bennett PH, Tuomilehto J, Schersten B, Pettitt DJ. Preventing non-insulin-dependent diabetes.  Diabetes. 1995;  44 483-488
• 10 Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, Inzucchi S, Dresner A, Rothman DL, Shulman GI. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes.  N Engl J Med. 1999;  341 240-246
• 11 Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents.  Ann Intern Med. 1990;  113 909-915
• 12 Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.  J Clin Endocrinol Metab. 1996;  81 4059-4067
• 13 Kim YB, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry RR, Kahn BB. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.  Diabetes. 2002;  51 443-448
• 14 Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.  Ann Intern Med. 1998;  128 176-185
• 15 Kubo K, Foley JE. Rate-limiting steps for insulin-mediated glucose uptake into perfused rat hindlimb.  Am J Physiol. 1986;  250 E100-E102
• 16 Lund S, Holman GD, Schmitz O, Pedersen O. Contraction stimulates translocation of glucose transporter GLUT4 in skeletal muscle through a mechanism distinct from that of insulin.  Proc Natl Acad Sci USA. 1995;  92 5817-5821
• 17 Welsh GI, Hers I, Berwick DC, Dell G, Wherlock M, Birkin R, Leney S, Tavare JM. Role of protein kinase B in insulin-regulated glucose uptake.  Biochem Soc Trans. 2005;  33 346-349
• 18 Lund S, Holman GD, Schmitz O, Pedersen O. Glut 4 content in the plasma membrane of rat skeletal muscle: comparative studies of the subcellular fractionation method and the exofacial photolabelling technique using ATB-BMPA.  FEBS Lett. 1993;  330 312-318
• 19 Marquie G, El Madani T, Solera ML, Duhault J, Espinal J, Khallayoun S, Bennani N. S15261, a novel agent for the treatment of insulin resistance. Studies on Psammomys obesus.  Life Sci. 1997;  61 1741-1753
• 20 Russell JC, Ravel D, Pegorier JP, Delrat P, Jochemsen R, O’Brien SF, Kelly SE, Davidge ST, Brindley DN. Beneficial insulin-sensitizing and vascular effects of S15261 in the insulin-resistant JCR:LA-cp rat.  J Pharmacol Exp Ther. 2000;  295 753-760
• 21 Duhault J, Lacour F, Boulanger M, Della-Zuana O, Ravel D, Wierzbicki M, Espinal J. S15261, a new compound for the treatment of the insulin resistance syndrome.  Diabetologia. 1994;  37 969-975
• 22 Henquin JC, Garrino MG, Nenquin M. Stimulation of insulin release by benzoic acid derivatives related to the non-sulphonylurea moiety of glibenclamide: structural requirements and cellular mechanisms.  Eur J Pharmacol. 1987;  141 243-251
• 23 DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization.  Diabetes. 1981;  30 1000-1007
• 24 Armstrong RB, Phelps RO. Muscle fiber type composition of the rat hindlimb.  Am J Anat. 1984;  171 259-272
• 25 Nesher R, Karl IE, Kaiser KE, Kipnis DM. Epitrochlearis muscle. I. Mechanical performance, energetics, and fiber composition.  Am J Physiol. 1980;  239 E454-E460
• 26 Wojtaszewski JF, Hansen BF, Urso B, Richter EA. Wortmannin inhibits both insulin- and contraction-stimulated glucose uptake and transport in rat skeletal muscle.  J Appl Physiol. 1996;  81 1501-1509
• 27 Lund S, Flyvbjerg A, Holman GD, Larsen FS, Pedersen O, Schmitz O. Comparative effects of IGF-I and insulin on the glucose transporter system in rat muscle.  Am J Physiol. 1994;  267 E461-E466
• 28 Tsao TS, Li J, Chang KS, Stenbit AE, Galuska D, Anderson JE, Zierath JR, MacCarter RJ, Charron MJ. Metabolic adaptations in skeletal muscle overexpressing GLUT4: effects on muscle and physical activity.  FASEB J. 2001;  15 958-969
• 29 Brozinick Jr JT, MacCoid SC, Reynolds TH, Nardone NA, Hargrove DM, Stevenson RW, Cushman SW, Gibbs EM. GLUT4 overexpression in db/db mice dose-dependently ameliorates diabetes but is not a lifelong cure.  Diabetes. 2001;  50 593-600
• 30 Daugaard JR, Richter EA. Relationship between muscle fibre composition, glucose transporter protein 4 and exercise training: possible consequences in non-insulin-dependent diabetes mellitus.  Acta Physiol Scand. 2001;  171 267-276
• 31 Cortez MY, Torgan CE, Brozinick Jr JT, Ivy JL. Insulin resistance of obese Zucker rats exercise trained at two different intensities.  Am J Physiol. 1991;  261 E613-E619
• 32 Pruett ED, Oseid S. Effect of exercise on glucose and insulin response to glucose infusion.  Scand J Clin Lab Invest. 1970;  26 277-285
• 33 Nyholm B, Qu Z, Kaal A, Pedersen SB, Gravholt CH, Andersen JL, Saltin B, Schmitz O. Evidence of an increased number of type IIb muscle fibers in insulin-resistant first-degree relatives of patients with NIDDM.  Diabetes. 1997;  46 1822-1828
• 34 Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action.  J Clin Invest. 2001;  108 1167-1174
• 35 Jessen N, Pold R, Buhl ES, Jensen LS, Schmitz O, Lund S. Effects of AICAR and exercise on insulin-stimulated glucose uptake, signaling, and GLUT-4 content in rat muscles.  J Appl Physiol. 2003;  94 1373-1379
• 36 Fujii N, Jessen N, Goodyear LJ. AMP-activated protein kinase and the regulation of glucose transport.  Am J Physiol Endocrinol Metab. 2006;  291 E867-E877

Correspondence